Pimasertib hydrochloride
Based on 10 publication(s) in Google Scholar
Pimasertib hydrochloride is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1236361-78-6
- Formule: C15H16ClFIN3O3
- Masse moléculaire:467.66
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pimasertib hydrochloride
More- Cell. 2023 Jun 22;186(13):2929-2949.e20. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Sci Adv. 2023 Mar 22;9(12):eadd5028. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Oncogenesis. 2019 Nov 4;8(11):65. [Abstract]
- Int Immunopharmacol. 2026 Apr 29:181:116734. [Abstract]
- Hong Kong Polytechnic University. 2025.
- Res Sq. 2025 Apr 14.
- Oncotarget. 2020 Nov 3;11(44):3921-3932. [Abstract]
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
Voir tous les produits spécifiques à Isoform MEK
More
Activité biologique
Chemical Information
-
CAS No. 1236361-78-6
-
Masse moléculaire 467.66
-
Formule C15H16ClFIN3O3
-
SMILES
OC[C@@H](O)CNC(C1=CC=NC=C1NC2=C(C=C(C=C2)I)F)=O.Cl
-
Synonyms
AS703026 hydrochloride; MSC1936369B hydrochloride
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell
Distinct longevity mechanisms across and within species and their association with aging. [Abstract]2023 Jun 22;186(13):2929-2949.e20. PMID: 37269831 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Sci Adv
Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding. [Abstract]2023 Mar 22;9(12):eadd5028. PMID: 36947620 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Oncogenesis
A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma. [Abstract]2019 Nov 4;8(11):65. PMID: 31685806 -
Int Immunopharmacol
The role and significance of YKL-40 in mucopathological remodeling in eosinophilic chronic rhinosinusitis. [Abstract]2026 Apr 29:181:116734. PMID: 42061140 -
-
-
Oncotarget
2020 Nov 3;11(44):3921-3932. PMID: 33216841 -
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077
Pureté et documentation
Références
[1]. Kim K, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol, 2010, 149(4), 537-549. [Content Brief]
[2]. Park SJ, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346(6):494-8. [Content Brief]
[3]. Yoon J, et al. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res, 2011, 71(2), 445-453. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pimasertib hydrochloride Related Classifications
HY-12042A Related Classifications
Powered by Bioz